• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

    10/30/24 1:50:00 PM ET
    $PLRZ
    Get the next $PLRZ alert in real time by email

    NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ:PLRZ).

    About Polyrizon Ltd.

    Polyrizon Ltd. is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Their proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a "biological mask" with a thin shield containment barrier in the nasal cavity. They're are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. They refer to their additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.

    For more information, visit https://www.polyrizon-biotech.com

    About Aegis Capital Corporation

    Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research, sales and trading services to institutional and retail investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.

    For more information about this offering or Investment Banking Services please email [email protected] or call (212) 813-1010.

    www.aegiscapcorp.com

    Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

    SOURCE: Aegis Capital Corp.



    View the original press release on accesswire.com

    Get the next $PLRZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLRZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLRZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

      Ra'anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based Trap & Target (T&T) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated that Polyrizon's hydrogel formulation achieves targeted deposition in the upper regions of the nasal cavity—critical for central nervous system (CNS) drug delivery. The promising results are part of a collaborative study between the Company and the Department of Food and Drug of the U

      6/12/25 7:32:00 AM ET
      $PLRZ
    • Polyrizon Announces Receipt of Nasdaq Delisting Notice

      Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), stating that based on its review of the Company's public filings with the Securities and Exchange Commission (the "SEC"), its staff has determined to delist the Company's securities pursuant to its discretionary authority under Listing Rule 5101. The receipt of the Nasdaq notification letter does not result in the immediate delisting of the

      5/23/25 4:15:00 PM ET
      $PLRZ
    • Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

      The Company demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models Raanana, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced compelling results from recent ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform. The studies were conducted in collaboration with Prof. Fabio Sonvico's laboratory, utilizing excised rabbit nasal mucosa as a surrogate for human nasal tissues. The research aimed to characterize two ke

      5/21/25 7:10:00 AM ET
      $PLRZ

    $PLRZ
    SEC Filings

    See more
    • SEC Form 6-K filed by Polyrizon Ltd.

      6-K - Polyrizon Ltd. (0001893645) (Filer)

      6/12/25 7:35:03 AM ET
      $PLRZ
    • SEC Form 6-K filed by Polyrizon Ltd.

      6-K - Polyrizon Ltd. (0001893645) (Filer)

      5/23/25 4:30:12 PM ET
      $PLRZ
    • SEC Form 6-K filed by Polyrizon Ltd.

      6-K - Polyrizon Ltd. (0001893645) (Filer)

      5/22/25 9:27:03 AM ET
      $PLRZ

    $PLRZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

      Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen

      12/19/24 7:22:00 AM ET
      $PLRZ
    • Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

      Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i

      12/13/24 6:25:00 AM ET
      $PLRZ